Related Experiment Video
Updated: Mar 17, 2026

Fabricating Superhydrophobic Polymeric Materials for Biomedical Applications
Published on: August 28, 2015
Deterred drug abuse using superabsorbent polymers
David J Mastropietro1, Srinath Muppalaneni1, Hossein Omidian1
1a Department of Pharmaceutical Sciences, College of Pharmacy , Nova Southeastern University , Fort Lauderdale , FL , USA.
Objective:
This study aimed to determine whether selected superabsorbent polymers (SAPs) could be used as a suitable alternative to thwart extraction, filtration, and syringeability attempts for abuse. Many abuse-deterrent formulations (ADFs) rely on high molecular weight polymers such as poly(ethylene oxide) to provide crush and extraction resistance. However, these polymers suffer from slow dissolution kinetics, and are susceptible to a variety of abuse conditions.
Methods:
Several commercially available SAPs were evaluated for swelling behavior in extraction solvents, and tableting properties. Post-compaction abuse properties were evaluated by recoverable volume and syringeability after solvent extraction. Drug release and percent drug extraction were conducted using tramadol HCl as a model drug.
Results:
Certain SAPs had the ability to rapidly imbibe solvent and effectively stop extraction processes in a variety of solvents, including water and water/alcohol mixtures. Tablets containing SAP and drug showed no effect on drug release in vitro.
Conclusions:
SAPs possess adequate properties for tableting, and maintain their high and fast swelling properties after compaction. The fast and extensive interactions of SAPs with aqueous medium are a major advantage over non-crosslinked high molecular weight viscosifying agents such as poly(ethylene oxide).
Related Concept Videos
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Drug Elimination by Renal Route: Tubular Reabsorption
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Modified-Release Drug Delivery Systems: Rate-Programmed II
Oral Drug Delivery Systems: Delayed-Release Systems

